The compound you described, **1-(2-chloro-10-phenothiazinyl)-2-[(1-methyl-5-tetrazolyl)thio]ethanone**, is more commonly known by its abbreviated name **chlorpromazine**.
**Chlorpromazine** is a **phenothiazine antipsychotic** that was first synthesized in 1950 and revolutionized the treatment of **schizophrenia** and other mental illnesses.
Here's why it's so important for research:
**1. Historical Significance:**
* **First effective antipsychotic:** Chlorpromazine was the first drug to effectively treat the positive symptoms of schizophrenia, such as hallucinations and delusions. This marked a significant breakthrough in the field of psychiatry, offering patients a new way to manage their symptoms and improve their quality of life.
* **Landmark in drug development:** It paved the way for the development of other antipsychotics, leading to a wider range of treatment options and improving the understanding of mental illnesses.
**2. Ongoing Research:**
* **Mechanism of action:** While chlorpromazine's precise mechanism of action is still under investigation, research continues to explore how it interacts with neurotransmitters like dopamine and serotonin to reduce psychotic symptoms. Understanding this mechanism is crucial for developing newer and more effective antipsychotics with fewer side effects.
* **New applications:** Scientists are investigating chlorpromazine's potential in treating other conditions, including:
* **Pain management:** Research suggests it may have analgesic properties.
* **Cancer treatment:** Some studies explore its use in treating certain cancers.
* **Neurodegenerative diseases:** Its potential benefits for conditions like Parkinson's disease and Alzheimer's disease are being explored.
**3. Understanding the Brain:**
* **Model for antipsychotic development:** Chlorpromazine serves as a benchmark for researchers developing new antipsychotic drugs. By understanding its strengths and weaknesses, scientists can strive to create medications with improved efficacy, fewer side effects, and better patient outcomes.
**In summary,** 1-(2-chloro-10-phenothiazinyl)-2-[(1-methyl-5-tetrazolyl)thio]ethanone, or chlorpromazine, holds immense historical and scientific significance. Its discovery revolutionized the treatment of mental illness, and ongoing research continues to explore its potential benefits and deepen our understanding of the brain and its complex workings.
ID Source | ID |
---|---|
PubMed CID | 1205193 |
CHEMBL ID | 1478317 |
CHEBI ID | 115089 |
Synonym |
---|
EU-0086749 |
MLS000050401 |
2-chloro-10-{[(1-methyl-1h-tetrazol-5-yl)thio]acetyl}-10h-phenothiazine |
smr000079654 |
1-(2-chloro-10h-phenothiazin-10-yl)-2-[(1-methyl-1h-tetrazol-5-yl)sulfanyl]ethanone |
STK203632 |
CHEBI:115089 |
MLS002547665 |
AKOS001737314 |
HMS2307F06 |
CHEMBL1478317 |
REGID_FOR_CID_1205193 |
Q27196932 |
1-(2-chloro-10-phenothiazinyl)-2-[(1-methyl-5-tetrazolyl)thio]ethanone |
1-(2-chloro-10h-phenothiazin-10-yl)-2-[(1-methyl-1h-1,2,3,4-tetraazol-5-yl)sulfanyl]-1-ethanone |
1-(2-chlorophenothiazin-10-yl)-2-(1-methyltetrazol-5-yl)sulfanylethanone |
Z18519426 |
Class | Description |
---|---|
phenothiazines | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 1.2589 | 0.0447 | 17.8581 | 100.0000 | AID485341 |
glp-1 receptor, partial | Homo sapiens (human) | Potency | 28.1838 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
TDP1 protein | Homo sapiens (human) | Potency | 23.2626 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
geminin | Homo sapiens (human) | Potency | 20.5962 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
lamin isoform A-delta10 | Homo sapiens (human) | Potency | 35.4813 | 0.8913 | 12.0676 | 28.1838 | AID1487 |
Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) | Potency | 6.3096 | 0.3162 | 12.7657 | 31.6228 | AID881 |
Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Potency | 6.3096 | 0.0063 | 8.2350 | 39.8107 | AID881 |
TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 39.8107 | 1.7783 | 16.2081 | 35.4813 | AID652104 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |